Terms: = Liver cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439 AND Treatment
31 results:
1. [Analysis and prediction of burden of viral hepatitis C-associated diseases in China from 1990 to 2044].
Zhou M; Yao L; Wu Y; Lin S; Huang J
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2023 Dec; 35(5):476-485. PubMed ID: 38148536
[TBL] [Abstract] [Full Text] [Related]
2. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
[TBL] [Abstract] [Full Text] [Related]
3. Uveal melanoma: In the era of new treatments.
Wespiser M; Neidhardt E; Negrier S
Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
[TBL] [Abstract] [Full Text] [Related]
4. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract] [Full Text] [Related]
5. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract] [Full Text] [Related]
6. [Effect evaluation of the primary screening strategy for liver cancer in rural areas of China].
Cao MM; Li H; Zha ZQ; Zhou JY; Luo PF; Gong JY; Ma HM; Sun XB; Chen WQ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):990-996. PubMed ID: 36164703
[No Abstract] [Full Text] [Related]
7. Tebentafusp for the treatment of hla-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract] [Full Text] [Related]
8. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.
Liu C; Liu H; Dasgupta M; Hellman LM; Zhang X; Qu K; Xue H; Wang Y; Fan F; Chang Q; Yu D; Ge L; Zhang Y; Cui Z; Zhang P; Heller B; Zhang H; Shi B; Baker BM; Liu C
Sci Rep; 2022 Jul; 12(1):12068. PubMed ID: 35840635
[TBL] [Abstract] [Full Text] [Related]
9. The Use of Molecular Dynamics Simulation Method to Quantitatively Evaluate the Affinity between HBV Antigen T Cell Epitope Peptides and hla-a Molecules.
Mei X; Li X; Zhao C; Liu A; Ding Y; Shen C; Li J
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563019
[TBL] [Abstract] [Full Text] [Related]
10. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D; Wells A; Clark AM
Sci Rep; 2022 Apr; 12(1):6657. PubMed ID: 35459800
[TBL] [Abstract] [Full Text] [Related]
11. Phase I/II Multicenter Trial of a Novel Therapeutic cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW; Gori S; Izzo F; Mayer-Mokler A; Ascierto PA; Königsrainer A; Ma YT; Sangro B; Francque S; Vonghia L; Inno A; Avallone A; Ludwig J; Alcoba DD; Flohr C; Aslan K; Mendrzyk R; Schuster H; Borrelli M; Valmori D; Chaumette T; Heidenreich R; Gouttefangeas C; Forlani G; Tagliamonte M; Fusco C; Penta R; Iñarrairaegui M; Gnad-Vogt U; Reinhardt C; Weinschenk T; Accolla RS; Singh-Jasuja H; Rammensee HG; Buonaguro L
Clin Cancer Res; 2022 Jun; 28(12):2555-2566. PubMed ID: 35421231
[TBL] [Abstract] [Full Text] [Related]
12. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
13. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract] [Full Text] [Related]
14. Anterior gradient 2-derived peptide upregulates major histocompatibility complex class I-related chains A/B in hepatocellular carcinoma cells.
Bian J; He L; Wu Y; Liu W; Ma H; Sun M; Yu J; Yu Z; Wei M
Life Sci; 2020 Apr; 246():117396. PubMed ID: 32035130
[TBL] [Abstract] [Full Text] [Related]
15. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma.
Song B; Zhen S; Meng F
Int Immunopharmacol; 2016 Dec; 41():35-41. PubMed ID: 27792920
[TBL] [Abstract] [Full Text] [Related]
16. NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma.
Lai RK; Xu IM; Chiu DK; Tse AP; Wei LL; Law CT; Lee D; Wong CM; Wong MP; Ng IO; Wong CC
Clin Cancer Res; 2016 Jun; 22(12):3105-17. PubMed ID: 26819450
[TBL] [Abstract] [Full Text] [Related]
17. Tumor MHC class I expression improves the prognostic value of T-cell density in resected colorectal liver metastases.
Turcotte S; Katz SC; Shia J; Jarnagin WR; Kingham TP; Allen PJ; Fong Y; D'Angelica MI; DeMatteo RP
Cancer Immunol Res; 2014 Jun; 2(6):530-7. PubMed ID: 24894090
[TBL] [Abstract] [Full Text] [Related]
18. Human leukocyte antigen class I alleles and haplotypes associated with primary hepatocellular carcinoma in persistent HBV-infected patients.
Pan N; Chen K; Qiu J; Sun H; Xu J; Miao F; Shi Q; Jiang W; Jin H; He Y; Xie W; Zhang J
Hum Immunol; 2013 Jun; 74(6):758-63. PubMed ID: 23459080
[TBL] [Abstract] [Full Text] [Related]
19. liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
[TBL] [Abstract] [Full Text] [Related]
20. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
[TBL] [Abstract] [Full Text] [Related]
[Next]
